Form 4: Calidi Biotherapeutics Director Exercises Warrants, Acquires Common Stock and New Warrants

James A. Schoeneck, a director at Calidi Biotherapeutics, exercised warrants to acquire common stock and new warrants, as part of an inducement offer.

Summary

• James A. Schoeneck, a director of Calidi Biotherapeutics, executed transactions involving warrants and common stock on June 3, 2024.
• Schoeneck exercised 173,000 Series B warrants and 375,000 Series C warrants at a reduced exercise price of $0.20 as part of an inducement agreement.
• The exercises resulted in the acquisition of common stock and new Series B-1 and C-1 warrants.
• Schoeneck also acquired 548,000 Series D warrants with an exercise price of $0.30 per share.
• These securities are held by the James & Cynthia Schoeneck Family Trust, for which Mr. Schoeneck is a trustee.
• Following these transactions, the James & Cynthia Schoeneck Family Trust beneficially owns 963,887 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The warrant exercises indicate insider confidence, but the potential dilution is a concern.

Positives

• The exercise of warrants demonstrates insider confidence in the company's prospects.
• The inducement agreement may encourage other warrant holders to exercise their warrants, providing additional capital to the company.

Risks

• The exercise of warrants could lead to dilution of existing shareholders' equity.
• The Series D warrants are initially exercisable upon receipt of stockholder approval, which may not be guaranteed.

Future Outlook

The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American.

Industry Context

Insider transactions are closely monitored as indicators of company health and management confidence. Warrant exercises can provide companies with additional capital but may also dilute existing shareholders.

Related Party Transactions

• The transactions involve a director, James A. Schoeneck, and the James & Cynthia Schoeneck Family Trust, indicating a related party transaction.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares upon warrant exercise.
• The company may benefit from the additional capital received from the warrant exercises.

Next Steps

• Stockholder approval may be required for the Series D warrants to become exercisable.

Key Dates